Nyxoah Inc. has announced a new single-arm study to evaluate the effectiveness of the Genio® System 2.1 for treating obstructive sleep apnea (OSA) in real-world clinical settings. Set to begin recruitment soon, this post-approval investigation aims to generate critical data on the system’s safety and performance for regulatory and medical stakeholders.
In this article:
What is the Genio® System 2.1?
The Genio® System 2.1 is a minimally invasive neurostimulator developed by Nyxoah Inc. It is designed to treat moderate to severe obstructive sleep apnea without requiring traditional continuous positive airway pressure (CPAP) machines. The device operates using bilateral hypoglossal nerve stimulation (HGN), targeting the root cause of OSA by keeping the airway open during sleep.
Current post-market surveillance indicates that Genio® may offer an innovative alternative for patients unable to tolerate CPAP therapy. This study will further validate its clinical effectiveness and safety in real-world implementations.
Study Details and Objectives
Nyxoah Inc. has structured this post-approval clinical trial as a single-arm design. All eligible and consenting participants will receive the Genio® System 2.1 implant, which combines a small, patient-controlled neurostimulator and an external activation device. The trial aims to confirm the device’s clinical efficacy and identify any performance variations over extended use in typical patient populations.
Specifically, the researchers plan to measure:
- Reduction in apnea-hypopnea index (AHI) over a defined period.
- Patient-reported quality of life improvements using standardized tools.
- Adverse device effects to evaluate its safety profile.
The findings will contribute to the growing body of evidence required by regulators and healthcare providers for broader acceptance of the implant.
Why This Study Matters to Stakeholders
The announcement comes as healthcare systems increasingly prioritize personalized and effective solutions for chronic conditions like sleep apnea. This study provides a critical opportunity to demonstrate safety and performance data in diverse patient populations beyond controlled research settings.
Regulatory bodies, clinicians, and patient advocacy groups alike may find the results instrumental in identifying candidates for Genio® as an alternative therapy option. It also underscores Nyxoah’s commitment to long-term market surveillance following medical device approval.
Frequently Asked Questions
- Who can participate in this study?
Participants must meet eligibility criteria, including a diagnosis of obstructive sleep apnea. Further details are expected in the official recruitment announcement. - Where will the study be conducted?
The exact sites have not yet been disclosed. Information will likely be shared in upcoming updates. - Is the study open to all patients?
The study will involve screened and consenting patients only. Recruitment is not yet open. - How is this study different from other clinical trials?
This post-approval trial focuses on practical, real-world applications and long-term data rather than initial safety and feasibility.
Conclusion and Next Steps
The study on Genio® System 2.1 marks an important phase in the ongoing evaluation of innovative therapies for obstructive sleep apnea. By bridging the gap between controlled trials and real-world patient experiences, it aims to strengthen clinical confidence in this next-generation technology.
Stakeholders across regulatory and medical communities should monitor updates as recruitment begins and findings are published.
Disclaimer
This content provides a generalized overview intended for professional audiences. It does not constitute medical or legal advice. Always refer to official regulatory documents when making decisions.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07331285?term=medical+device